مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

46
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

11
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Medication Cost of Enzyme Replacement Therapy for Mucopolysaccharidoses in Iran

Pages

  14988-14996

Abstract

 Background: The mucopolysaccharidoses (MPSs) are a group of rare inherited metabolic disorders caused by lack or insufficient activity of lysosomal enzymes. Although no cure has been identified until now, Enzyme replacement therapy (ERT) can reduce symptoms of some types of MPSs. providing ERT for patients is a challenge for health systems due to expensivity of the medicines. In this study, we aimed to examine the average annual cost of medicines used for ERT per patient in Iran healthcare system. Methods: Data on patients were consolidated from different sources of Iran Food and Drug Administration’, s (IFDA). After collecting data, patients with MPS I, IV, and VI were categorized into five age groups (5-years interval). The number of vials distributed monthly was used for the estimation of the annual medication cost for each patient and compared against the Gross Domestic Product (GDP) per capita. Results: Data on 185 patients with MPS was analyzed. The frequency of patients with MPS I, IV, and VI was 27, 40. 6, and 32. 4%, respectively. The average annual expenditure on ERT medications per patient was estimated at 206. 07 United States Dollars. The average annual cost has shown to be about 38 times the current GDP per capita of the country. Conclusions: The medication cost of ERT for MPS disease is substantial to the health system. To ensure the best clinical effectiveness and efficient use of financial resources, it is highly recommended that healthcare policymakers use an evidence-based clinical practice guideline and improve the data quality in rare diseases registry.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    Nabizadeh, Azita, Kheirandish, Mehrnaz, Gharibnaseri, Zahra, Oloomi, Naghmeh, AZIZI, FATEMEH, & Moradi, Najmeh. (2021). Medication Cost of Enzyme Replacement Therapy for Mucopolysaccharidoses in Iran. INTERNATIONAL JOURNAL OF PEDIATRICS, 9(12 (96)), 14988-14996. SID. https://sid.ir/paper/994947/en

    Vancouver: Copy

    Nabizadeh Azita, Kheirandish Mehrnaz, Gharibnaseri Zahra, Oloomi Naghmeh, AZIZI FATEMEH, Moradi Najmeh. Medication Cost of Enzyme Replacement Therapy for Mucopolysaccharidoses in Iran. INTERNATIONAL JOURNAL OF PEDIATRICS[Internet]. 2021;9(12 (96)):14988-14996. Available from: https://sid.ir/paper/994947/en

    IEEE: Copy

    Azita Nabizadeh, Mehrnaz Kheirandish, Zahra Gharibnaseri, Naghmeh Oloomi, FATEMEH AZIZI, and Najmeh Moradi, “Medication Cost of Enzyme Replacement Therapy for Mucopolysaccharidoses in Iran,” INTERNATIONAL JOURNAL OF PEDIATRICS, vol. 9, no. 12 (96), pp. 14988–14996, 2021, [Online]. Available: https://sid.ir/paper/994947/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button